Reviewed for Clinical Accuracy by the InVita Wellness Clinical Team
Two names come up constantly in conversations about growth hormone optimization. Tesamorelin and sermorelin. Both are growth hormone releasing hormone analogs used in physician guided practice, and both get discussed as though they were interchangeable versions of the same idea.
They are not interchangeable, and the difference is clinical rather than cosmetic.
The usual framing is that sermorelin is the gentle option and tesamorelin is a stronger version of the same thing. That framing is not exactly wrong, but it skips everything that actually decides the question. Where an individual’s growth hormone axis currently sits. What the metabolic profile looks like. What each compound has actually been studied for, and in whom. And what each one’s regulatory position means in practice, which is where most articles on this subject go badly astray.
What follows is education rather than promotion, and one distinction belongs up front. Tesamorelin is available in the United States as an FDA approved product for one narrow indication. There is no FDA approved sermorelin product marketed in the United States today, so sermorelin dispensed now is a compounded preparation, which is not FDA approved and is not reviewed by FDA for safety, effectiveness, or quality before it reaches a patient. Both are injectable prescription therapies requiring physician oversight, baseline bloodwork, ongoing monitoring, and informed consent. Neither is appropriate for self administration. If you are exploring peptide therapy seriously, this comparison is a starting point for a consultation and not a substitute for one.
Quick Answer
- Sermorelin is the first 29 amino acids of natural GHRH, the shortest fragment that still activates the pituitary receptor.
- Tesamorelin is a modified analog of the full 44 amino acid sequence, stabilized against enzymatic breakdown, and daily dosing produces a large and sustained rise in IGF-1. Tesamorelin holds the only FDA approval in this class, and it is narrow, covering reduction of excess abdominal fat in adults with HIV associated lipodystrophy.
- Sermorelin was approved as Geref, first in 1990 as a diagnostic agent and again in 1997 for growth hormone deficiency in children, and both applications were withdrawn in 2009 after the manufacturer discontinued the product for business reasons. FDA later determined that Geref was not withdrawn for safety or effectiveness reasons, a determination whose stated purpose was to permit approval of abbreviated applications if all other legal and regulatory requirements are met.
- Whether a particular compounded sermorelin preparation may lawfully be dispensed today depends on current federal and state requirements and is a question for the prescriber and the dispensing pharmacy.
- Neither compound has been studied in a long randomized trial for age related growth hormone decline, and we are not aware of a direct head to head trial between them. The choice is a clinical evaluation, not a table.
Medical Disclaimer
This article is for educational and informational purposes only and does not constitute medical advice. Some therapies discussed may involve off-label use of FDA-approved medications or compounded medications that are not FDA-approved. Treatment decisions should be based on an individual clinical evaluation and, when appropriate, laboratory testing and ongoing monitoring.
Individual responses vary, and no specific outcome is guaranteed. Regulatory, prescribing, and compounding requirements may change over time; current availability and appropriateness should be confirmed with a qualified healthcare provider and dispensing pharmacy
How the Growth Hormone Axis Works
Growth hormone is produced by the anterior pituitary in response to two opposing hypothalamic signals. GHRH stimulates release and somatostatin inhibits it. That push and pull produces the pulsatile pattern of healthy physiology, with the largest pulses arriving during deep sleep.
Growth hormone is produced by the anterior pituitary in response to two opposing hypothalamic signals. GHRH stimulates release and somatostatin inhibits it. That push and pull produces the pulsatile pattern of healthy physiology, with the largest pulses arriving during deep sleep.
The clinically significant downstream effect is IGF-1 production in the liver. IGF-1 mediates much of what growth hormone is credited with, including body composition, tissue repair, metabolic regulation, and recovery. It is also the marker that gets measured, because circulating growth hormone is too pulsatile to interpret from a single draw. When a physician talks about growth hormone status, what is actually on the page in front of them is an IGF-1 value read against an age adjusted reference.
What Happens With Age
Growth hormone secretion falls progressively across adult life, a process often called somatopause. By the fifties and sixties both output and circulating IGF-1 may be substantially below early adult levels. The associated picture is familiar enough. Gradual visceral fat accumulation, reduced lean mass, slower recovery, changes in sleep quality, lower energy, shifting lipids.
Two cautions belong next to that. These changes are multifactorial, and declining growth hormone is one contributor among several. And the resemblance between age related decline and diagnosed adult growth hormone deficiency is a resemblance, not an equivalence. Not everyone experiencing these changes has clinically meaningful growth hormone decline, and a reduced IGF-1 on its own does not make someone a candidate for anything.
Why Visceral Fat Is the Clinical Target
Visceral fat, the deep abdominal fat surrounding the internal organs, behaves differently from subcutaneous fat. It is metabolically active, and it is associated with raised inflammatory markers, insulin resistance, dyslipidemia, and elevated cardiovascular risk.
It also appears more responsive to growth hormone signaling than subcutaneous fat. That asymmetry is why tesamorelin was developed and studied for this specific outcome, and it explains an otherwise odd trial finding, that visceral fat fell significantly while body weight was essentially unchanged.
Sermorelin, the Foundational Approach
What it is and how it works
Sermorelin is a synthetic analog of the first 29 amino acids of endogenous GHRH, the minimum sequence that still binds the pituitary GHRH receptor and triggers release. Work in the early 1980s established that this fragment retains biological activity, which is why nothing longer was needed.
It activates GHRH receptors on somatotroph cells of the pituitary and promotes release of the body’s own growth hormone in a pulsatile fashion. Release stays under the control of the existing regulatory system, including somatostatin feedback. Half life is short, roughly ten to twenty minutes, which puts it in the pulse region rather than the plateau.
The regulatory position, which is more interesting than it sounds
Most articles reduce this to a single line about Geref being discontinued in 2008. The sequence matters more than the summary.
Sermorelin acetate was approved twice. Geref Diagnostic, NDA 19-863, was approved on 28 December 1990 as a diagnostic agent for pituitary function. Geref, NDA 20-443, was approved on 26 September 1997 for idiopathic growth hormone deficiency in children with growth failure. EMD Serono discontinued both products in 2008 for business reasons and asked FDA to withdraw the applications, and FDA withdrew approval in 2009. In a notice published in the Federal Register on 4 March 2013, FDA determined that Geref had not been withdrawn from sale for reasons of safety or effectiveness.
The stated purpose of that determination is procedural. It permits FDA to approve abbreviated new drug applications referencing Geref if all other legal and regulatory requirements are met. It is a finding about why the product left the market. It is not, by itself, an authorization for any particular downstream use.
That distinction is the one most consumer articles collapse. Whether a compounding pharmacy may lawfully prepare sermorelin for a given patient today turns on current federal and state compounding requirements rather than on the 2013 notice alone, and it should be verified with the prescriber and the dispensing pharmacy at the time of treatment.
What sermorelin lacks is an FDA approved product marketed in the United States today. Compounded preparations are made by licensed pharmacies under state pharmacy board oversight and applicable USP standards. They are not FDA approved, and FDA does not review them for safety, effectiveness, or quality before they are dispensed the way it reviews an approved drug product.
What the evidence suggests
Sermorelin’s evidence base in the general adult wellness population is observational and clinical rather than trial based. It has not been evaluated in large long term randomized controlled trials for age related growth hormone decline. What exists is extrapolation from GHRH physiology, open label clinical experience, and the broader literature on growth hormone in adult health.
That should be read as mechanistically plausible rather than established. Accounts of improved sleep quality, body composition, recovery, and energy after several months of use come from clinical observation and patient report, not from controlled trials, and they carry the limitations that implies. Individual responses vary and no timeframe or outcome can be promised.
Protocol duration
No controlled trial establishes a minimum treatment duration for wellness use. In physician directed practice, several months are usually allowed before any judgment about response is made, and at InVita that reassessment typically falls in the three to six month range. Shorter self directed trials rarely produce information worth acting on.
Side effects and risks
Reported effects are generally mild and local in appropriate candidates.
- Injection site reactions such as redness, swelling, or discomfort, the most commonly reported effect
- Flushing, headache, or dizziness, usually transient
- Nausea in some people, particularly early in treatment
- Fluid retention or mild edema, which follows from GH and IGF-1 stimulation
- Changes in glucose and insulin. Growth hormone stimulation can affect insulin sensitivity, so glucose is evaluated at baseline and monitored during the protocol
It is worth separating what is documented from what is inferred. The first two items were described during the approved Geref era and were largely transient, resolving after discontinuation. Fluid retention and changes in glucose handling are inferred from what GH and IGF-1 stimulation does as a class, and they have not been quantified for compounded sermorelin in wellness populations. Long term safety data in healthy adults using it for age related decline are limited in duration. That is a gap in the evidence rather than a specific safety signal.
Tesamorelin, the Targeted Approach
What it is and how it works
Tesamorelin is a synthetic analog of the full 44 amino acid growth hormone releasing factor sequence, with a hexenoyl group attached to the tyrosine residue at the N terminal end of the molecule. That modification improves stability against enzymatic degradation relative to native GHRF. It does not give tesamorelin a long circulating half life. The prescribing information reports a mean elimination half life of about 8 minutes after subcutaneous administration, so the pharmacology remains pulse like rather than sustained.
What daily dosing does produce is a large and sustained IGF-1 response. In the pivotal trials, the mean treatment difference over placebo at 26 weeks was roughly 105 to 122 ng/mL.
Comparisons online routinely describe tesamorelin as far more potent than sermorelin. We are not aware of a direct head to head clinical trial between the two. What can be said is that tesamorelin has been studied at a defined dose against placebo with measured endpoints and sermorelin has not been studied that way in this population. That is a difference in the quality of the evidence, not a measured difference in potency, and it should not be presented as one.
What the FDA approval covers, and what it does not
Tesamorelin is approved for one indication, reduction of excess abdominal fat in adults with HIV associated lipodystrophy, based on randomized placebo controlled trials that measured visceral adipose tissue by CT imaging. Use for general body composition, metabolic optimization, or longevity in people without that diagnosis is off label. Off label prescribing is legal and commonplace, but it means using the product for outcomes that the approval process did not evaluate.
One claim is worth correcting directly, because it appears constantly. The label states that tesamorelin is not indicated for weight loss management and describes the effect as weight neutral. In the pivotal trials, mean body weight changed by less than half a kilogram in either direction. It redistributes fat away from the visceral compartment. Anyone marketing it as a weight loss compound is contradicting the label.
What the evidence suggests for general wellness use
There are no controlled trial data for tesamorelin in non HIV wellness populations. Benefits described in that context rest on mechanism, on clinical experience, and on extrapolation from the lipodystrophy trials and the physiology of the axis. Controlled efficacy for general wellness use has not been established, and anyone considering it outside the approved indication should understand that before starting treatment.
Protocol duration and the discontinuation question
In the two pivotal studies, visceral adipose tissue fell by a mean of 18 percent and 14 percent respectively over 26 weeks, measured by CT at the L4 to L5 level, against small changes on placebo. The 52 week extension then addressed the question that matters most for planning. What happens when treatment stops?
Patients who continued tesamorelin through week 52 held their week 26 reduction, with a mean change of plus 3 cm² in one study and minus 11 cm² in the other. Patients re randomized to placebo at week 26 regained visceral fat, with mean increases of 25 cm² and 24 cm², roughly 22 percent and 16 percent above their week 26 values. Those are group averages rather than individual outcomes, and they do not mean every person returned precisely to a starting point. The direction is unambiguous, though. Visceral fat reaccumulates once treatment stops.
This is not a safety issue and it is not a criticism of the compound. It is a fact relevant to deciding what kind of intervention this is. Tesamorelin produces an ongoing physiological effect rather than a permanent change, which has consequences for cost, commitment, and how anyone should approach starting.
Side effects and risks
The tesamorelin safety picture is better characterized than the sermorelin picture, because it comes from controlled trials. Adverse reactions reported in more than 5 percent of treated patients were arthralgia, injection site erythema, injection site pruritus, pain in extremity, peripheral edema, and myalgia. Injection site reactions occurred in 25 percent of treated patients versus 14 percent on placebo, and hypersensitivity reactions in 4 percent.
Three items belong in any honest account.
Glucose. In the trials, the proportion of patients with an elevated HbA1c of 6.5 percent or above from baseline to week 26 was 5 percent on tesamorelin and 1 percent on placebo, with a hazard ratio of 3.3 (CI 1.4, 9.6). The label directs that glucose status be evaluated before starting and that all treated patients be monitored periodically for impaired glucose tolerance or diabetes. It also directs that patients with diabetes be checked at regular intervals for development or worsening of retinopathy.
Immunogenicity. Anti tesamorelin IgG antibodies were detected in 50 percent of patients treated for 26 weeks and 47 percent of those treated for 52 weeks. Cross reactivity with endogenous GHRH was seen in approximately 60 percent of those who developed antibodies. Patients with and without antibodies had similar mean reductions in visceral adipose tissue and similar IGF-1 responses. Neutralizing antibodies to tesamorelin and to human GHRH were detected in vitro at week 52 in 10 percent and 5 percent of treated patients respectively. The label reports these findings without drawing a conclusion beyond them.
IGF-1 and malignancy. The label carries a warning for increased risk of neoplasms, contraindicates use in active malignancy, and requires that any preexisting malignancy be inactive and its treatment complete before starting. IGF-1 monitoring is directed during therapy, with discontinuation considered for persistent elevations. Among patients treated for 26 weeks, 47 percent had IGF-1 above 2 standard deviation scores and 36 percent above 3. The approval trials were not designed or powered to detect a malignancy signal, so their result does not establish that the risk is absent.
Tolerability in practice shows up in the discontinuation figures. During the first 26 weeks, discontinuations due to adverse reactions occurred in 9.6 percent of patients on tesamorelin and 6.8 percent on placebo.
Side by Side Comparison
The table sets out what is documented for each compound. It does not select between them.
Structure
First 29 amino acids of GHRH
Full 44 amino acid GHRF sequence with a hexenoyl group at the N terminal tyrosine
Mechanism
GHRH receptor agonist, pulsatile GH release, short half life of roughly 10 to 20 minutes
GHRF receptor agonist. Stabilized against enzymatic degradation. Label reports a mean elimination half life of about 8 minutes
Clinical goal
Gradual physiological GH support
Reduction of excess abdominal fat in the approved population
Evidence base
Older approval history in diagnostic and pediatric use. Observational and open label experience in adults. No RCT data in wellness populations
Phase III randomized placebo controlled data in HIV associated lipodystrophy only. No controlled data in general wellness
Regulatory status
Approved as Geref in 1990 and 1997. Discontinued by the manufacturer for business reasons, applications withdrawn in 2009. FDA determined the withdrawal was not for safety or effectiveness reasons. No FDA approved product marketed today, so it is dispensed as a compounded preparation
FDA approved for reduction of excess abdominal fat in HIV associated lipodystrophy. Off label for general wellness. Explicitly not indicated for weight loss
Studied duration
No controlled trial defines a minimum duration. Practice generally allows several months before response is judged
26 weeks to the primary endpoint, with 52 week extension data. Visceral fat reaccumulates after discontinuation
Reported side effects
Injection site reactions, flushing, headache, fluid retention, changes in glucose handling
Arthralgia, injection site erythema and pruritus, pain in extremity, peripheral edema, myalgia
Selection is a clinical judgment rather than a table lookup. The factors a physician weighs include the working diagnosis, baseline IGF-1 read against an age adjusted reference, glucose regulation, personal and family medical history, current medications, labeled contraindications, the specific goal being pursued, and how well the available evidence applies to that goal. One point is worth stating plainly. An IGF-1 meaningfully below the age adjusted range is a reason to evaluate for growth hormone deficiency or pituitary disease, not in itself a reason to select one compound over the other in a wellness setting.
What the Research Actually Shows
lt-blog__border–text width100″ style=”margin-top: 0;”>The strongest evidence for either compound on visceral fat and metabolic outcomes comes from the randomized placebo controlled trials supporting the tesamorelin approval. Those trials enrolled HIV positive adults with antiretroviral associated lipodystrophy and demonstrated significant visceral adipose reductions by CT imaging, along with triglyceride improvements. They also produced the extension data on reaccumulation described above.
The evidence gap between the two is not symmetrical, and the difference is worth stating precisely. Tesamorelin has controlled efficacy and safety data, but in one specific population with one specific condition. Sermorelin has an older approval history in diagnostic and pediatric use and observational experience in adults. What both share is the absence of controlled evidence for age related growth hormone decline in otherwise healthy adults, which is the generalizability problem rather than an equivalence of evidence.
A reader who discounts sermorelin for thin evidence and accepts tesamorelin because it carries an FDA approval is still making a category error, since that approval covers a different population with a different condition.
Who Is Not an Appropriate Candidate
Contraindications in the tesamorelin label
These are the contraindications stated in the FDA approved prescribing information for tesamorelin.
- Disruption of the hypothalamic pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation, or head trauma
- Active malignancy. Any preexisting malignancy should be inactive and its treatment complete before starting
- Known hypersensitivity to tesamorelin or to the excipients, which include mannitol
- Pregnancy
Other factors requiring physician evaluation
These are considerations a physician weighs rather than labeled contraindications. Compounded sermorelin does not carry FDA approved labeling, so there is no equivalent labeled contraindication list for it, and these factors are applied on clinical grounds.
- A history of malignancy, including non malignant neoplasms, which calls for careful evaluation before treatment is considered
- Impaired glucose regulation, prediabetes, or diabetes
- IGF-1 already in the upper part of the age adjusted range
- Active inflammatory conditions or acute illness
- Breastfeeding
- Acute critical illness, where the label directs that discontinuation be considered
Neither compound is appropriate for self administration without medical supervision.
When to seek a medical assessment rather than a wellness consultation
Unexplained weight loss, night sweats, a new or changing lump, persistent abdominal swelling, new numbness or tingling in the hands that wakes you at night, visual changes or persistent headaches, or fatigue that arrived abruptly over days rather than gradually over years. Some of these overlap with growth hormone axis pathology and some do not, but none of them are peptide questions. They warrant a physician assessment first.
Cost and Access
Both compounds are cash pay in wellness contexts. Insurance coverage varies by payer, plan, product, and indication, and off label use for general wellness may not be covered. That is worth confirming with your own plan rather than assuming either way.
Cost depends on the protocol, dose, and duration, and is best discussed in detail at consultation. One point belongs in that conversation specifically. Because the visceral fat effect of tesamorelin reaccumulates after discontinuation, the cost of a first protocol is not the cost of maintaining an effect. That is the question worth asking, rather than the price of any single month.
How Decisions Are Made at InVita
Peptide decisions at InVita follow a structured physician evaluation, and the prescribing physician stays involved through the protocol rather than only at initiation.
Baseline laboratory work is ordered before anything is considered and may include serum IGF-1, fasting insulin, fasting triglycerides, a full lipid panel, and a comprehensive metabolic panel. Additional markers may be added based on individual history and presentation.
If a protocol is appropriate, it covers compound selection, dosing, administration guidance, and a monitoring schedule. IGF-1 is retested at intervals. Glucose and metabolic markers are checked at baseline and monitored during treatment rather than only at intake, which is explicitly directed in the tesamorelin labeling and is applied as a clinical precaution with sermorelin as well, since compounded sermorelin carries no labeling of its own. Protocols are individualized, and response is assessed against laboratory data and clinical picture rather than against how someone feels at week three.
1
STEP 1:
Baseline Assessment
- Pre-Treatment Lab Work: Comprehensive diagnostics are required before any protocol is considered.
- Core Panel: Measures serum IGF-1, fasting insulin, fasting triglycerides, full lipid panel, and a comprehensive metabolic panel (CMP).
- Individualized Testing: Additional health markers are added based on patient history and clinical presentation.
2
STEP 2:
Personalized Protocol Design
- Individualized Setup: Covers compound selection, precise dosing, and administration guidance tailored to the patient.
- Monitoring Schedule: Establishes a structured timeline for follow-up testing and clinical review.
- Continuous Care: The prescribing physician remains actively involved throughout the entire protocol, not just at initiation.
3
STEP 3:
Ongoing Monitoring & Re-Evaluation
- Intermittent IGF-1 Checks: Serum IGF-1 is retested at defined intervals to track physiological response.
- Glucose & Metabolic Safety: Glucose and metabolic markers are monitored during treatment (explicitly required for Tesamorelin and applied as a precaution for Sermorelin).
- Data-Driven Assessment: Treatment response is judged against objective lab data and full clinical outcome—never against short-term subjective feelings (e.g., how a patient feels at week three).
Frequently Asked Questions
Is sermorelin FDA approved?
Not currently, and the full answer is more useful than yes or no. Sermorelin was approved as Geref Diagnostic in 1990 and as Geref in 1997 for growth hormone deficiency in children. The manufacturer discontinued both in 2008 for business reasons, and the applications were withdrawn in 2009. In 2013 FDA determined that the withdrawal was not for reasons of safety or effectiveness. There is no FDA approved sermorelin product marketed in the United States today, so sermorelin dispensed now is a compounded preparation, which is not FDA approved and is not reviewed by FDA for safety, effectiveness, or quality before dispensing. Whether it may lawfully be compounded for a particular patient is governed by current federal and state requirements and is a question for the prescriber and the pharmacy.
Is sermorelin safe?
Under physician supervision it has a long tolerability record in appropriate candidates, and reported effects are mostly local and mild, such as injection site reactions, flushing, or headache. Fluid retention and changes in glucose handling can follow from GH and IGF-1 stimulation, which is why glucose is checked at baseline and during the protocol. Long term safety data in healthy adults using it for age related decline are limited in duration. That is a gap in the evidence rather than a documented problem.
Does sermorelin cause cancer?
Available evidence has not established that sermorelin causes cancer. The concern is indirect but clinically real. GH and IGF-1 signaling is involved in cell proliferation, which is why active malignancy and certain cancer histories are contraindications across this class and why IGF-1 is monitored during a protocol. That is a precaution grounded in mechanism, not a finding of higher cancer rates in studies.
What does tesamorelin do?
It signals the pituitary to release more of the body’s own growth hormone, which raises IGF-1, which in turn mobilizes fat preferentially from the visceral compartment. In the approved population it reduced visceral adipose tissue by a mean of 14 to 18 percent over 26 weeks, measured on CT. What it does not do is reduce body weight. The label describes the effect as weight neutral and states that the product is not indicated for weight loss management.
Is tesamorelin a steroid?
No. Steroids are lipid molecules that act on intracellular hormone receptors. Tesamorelin is a peptide, a chain of amino acids, that acts on a cell surface receptor in the pituitary. It does not introduce an external hormone. It signals the pituitary to release growth hormone the body produces itself, within the existing feedback system of that axis.
Is tesamorelin safe?
It has controlled safety data, with one item that gets specific attention. Common reactions are joint pain, injection site reactions, fluid retention, and muscle aches. Glucose is the item to watch. An elevated HbA1c of 6.5 percent or above occurred in 5 percent of treated patients versus 1 percent on placebo, with a hazard ratio of 3.3 (CI 1.4, 9.6). The label directs evaluation of glucose status before starting and periodic monitoring during treatment. If fasting insulin or HbA1c is already borderline, that changes the calculation considerably.
Does tesamorelin work, and how long does it take?
In the population it was approved for, yes, with CT measured endpoints behind it. Visceral fat reductions were statistically significant at the 26 week primary endpoint. The trials were not designed to establish when an individual first notices a change, so specific timelines quoted elsewhere are not coming from controlled data. Outside that population there is no controlled evidence, only mechanism and clinical experience. And the extension data show that visceral fat reaccumulates after treatment stops.
How is the choice between them made?
By evaluation rather than by comparison table, and not by self selection. What a physician assesses includes baseline IGF-1 against an age adjusted reference, metabolic markers such as fasting insulin, triglycerides and HbA1c, body composition, medical history, current medications, labeled contraindications, and whether the available evidence actually supports the goal being pursued. Neither compound has controlled evidence for age related growth hormone decline in healthy adults, so that evaluation is where the decision has to come from.
Taking the Next Step
If the clinical profiles described here are relevant to your situation, the next step is a physician consultation rather than a decision made from a comparison table. An InVita peptide consultation starts with a full health history and baseline bloodwork. Where a protocol is appropriate, recommendations follow from that evaluation rather than preceding it.
Explore peptide therapy
contact InVita Wellness today
Book Now
456 Broadway 2 Floor, New York, NY 10013, USA
InVita Wellness is a physician guided longevity and wellness practice in SoHo, New York City, serving clients from Manhattan, Brooklyn, and the surrounding metropolitan area.
This article is intended for educational purposes only and does not constitute medical advice. A physician evaluation is required before any peptide protocol is considered. Individual results vary and are not guaranteed.
References
- EGRIFTA SV (tesamorelin) for injection, full prescribing information. DailyMed, U.S. National Library of Medicine.
[DailyMed]
- EGRIFTA (tesamorelin for injection) label, 2010 approval. U.S. Food and Drug Administration.
[FDA]
- EGRIFTA WR (tesamorelin) for injection, full prescribing information. DailyMed, U.S. National Library of Medicine.
[DailyMed]
- Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register, 4 March 2013.
[Federal Register]
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone releasing factor in patients with HIV. N Engl J Med. 2007;357:2359-2370.
[NEJM]
- Falutz J, Mamputu JC, Potvin D, et al. Long term safety and effects of tesamorelin, a growth hormone releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008.
[PubMed]
- Junnila RK, List EO, Berryman DE, Murrey JW, Kopchick JJ. The GH/IGF-1 axis in ageing and longevity. Nat Rev Endocrinol. 2013;9(6):366-376.
[PubMed]
- TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy. NCT00608023.
[ClinicalTrials.gov]
